Real-life data of survival and reasons for discontinuation of biological disease-modifying drugs ‘in’ rheumatoid arthritis

International Journal of Clinical Pharmacy

Fecha de publicación: 21 de octubre de 2020

Autores: Ana Paula Monteiro Gomides, Cleandro Pires de Albuquerque, Ana Beatriz Vargas Santos, Manoel Barros Bértolo, Paulo Louzada Júnior, Rina Dalva Neubarth Giorgi, Sebastião Cezar Radominski, Maria Fernanda B. Resende Guimarães, Karina Rossi Bonfiglioli, Maria de Fátima Lobato da Cunha Sauma, Ivânio Alves Pereira, Claiton Viegas Brenol, Licia Maria Henrique da Mota & Geraldo da Rocha Castelar Pinheiro 

DOI: https://doi.org/10.1007/s11096-020-01171-5

Background: Rheumatoid arthritis is a chronic, autoimmune disease in which treatment has evolved with a variety of therapeutic classes. Biological disease-modifying antirheumatic drugs have improved therapy; however, the continued long-term use of these drugs with sustained safety and efficacy remains a challenge.

Leer más